RecruitMe Clinical Trial

A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
CB-839 With Radiation Therapy and Temozolomide in Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
Sponsor:National Cancer Institute NCI
Enrolling:Male and Female Patients
Minimum Age:16 years old
IRB Number:AAAS3546
U.S. Government ID:NCT03528642
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to test the safety of the investigational study drug CB-839 when used in combination with radiation therapy and temozolomide chemotherapy. This study tests different doses of CB-839 to see which dose is safer for people. There will be up to 40 people taking part in this study. Another purpose of this study is to test magnetic resonance spectroscopy (MRS) scans, which are a way to take pictures of your type of cancer. MRS scans are based on the same technology as MRI scans, however MRI scans evaluate the structure of your brain while MRS scans evaluate the amount of various chemicals in your brain. The study doctors want to see if MRS scans are able to detect changes in certain tumor markers because of treatment with the highest dose of CB-839 when used in combination with radiation and temozolomide. The MRS scans done in this study will not be combined with any planned clinical MRI scans. There will be about 10 people taking part in this study as part of the expansion part.

Do You Qualify?
Are you 16 years of age or older?YesNo
Do you have IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma?YesNo
Are you able to carry out work of a light or sedentary nature, e.g., light house work, office work?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162